Evaluation of the permeation of antineoplastic agents through medical gloves of varying materials and thickness and with varying surface treatments

Table 2 UPLC-MS/MS conditions and settings

Analyte	Monitor ion [m/z]	Column^a	Flow [mL/min]	Composition (solvent A/solvent B)^b			LOQ [ng/mL]
ETP^c	589.5 > 229.1	A	0.3	30/70 (isocratic)			50
CPA^d	261.1 > 139.7	A	0.3	30/70 (isocratic)			40
DXR	544.4 > 397.2	A	0.3	0–3 3–4.5 4.5–5.5	min min min	90/10 90/10 → 10–90 90/10	50
PTX	854.6 > 286.0	A	0.3	0–3 3–4.5 4.5–5.5	min min min	70/30 70/30 → 10–90 70/30	200
5FU	128.6 > 85.6^e	B	0.3	50/50 (isocratic)^g			100
Gemcitabine^f	264.1 > 111.6	B	0.3	50/50 (isocratic)^g			-

^aColumn A, ACQUITY UPLC BEH® Shield RP18 (1.7 μm, 2.1 × 100 mm); column B, ACQUITY UPLC BEH® AMIDE (1.7 μm, 2.1 × 150 mm)
^bSolvent A, 0.1% (v/v) formic acid in water; solvent B, 0.1% (v/v) formic acid in acetonitrile
^cAlso used as internal standard for CPA, DXR, and PTX
^dAlso used as internal standard for ETP
^e5FU was detected by negative ion mode whereas the other compounds were detected by positive ion mode
^fInternal standard for 5FU
^gWater/acetonitrile = 50/50 (without 0.1% formic acid)

ISSN: 2055-0294